Interaction Color Code
Clinical Bottom Line
Do not coadminister: Potential for reduced levels of doravirine
Drug 1
Drug 2
Mechanism
Strong CYP3A4 induction
Clinical Effects
Potential decrease in antiretroviral efficacy
Management
Contraindicated. Use alternative agents. If discontinuing enzalutamide, a minimum 4 week cessation period is recommended prior to initiating doravirine.
Import ID
348
